Oveporexton: The first-in-class orexin receptor 2 (OX2R) agonist approved for treatment of narcolepsy type 1 (NT1)
Drug Discoveries & Therapeutics · 31.08.2026 · 20 (4) · 357-359
DOI: 10.5582/ddt.2026.01056 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Discoveries & Therapeutics, erschienen am 31.08.2026. Verfasst von Yueyi Sun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Narcolepsy, Orexin Receptors, Benzoxazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Narcolepsy type 1 (NT1) is a chronic neurological disorder caused by selective loss of orexin-producing neurons, resulting in unstable sleep-wake regulation and characteristic symptoms including excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic or hypnopompic hallucinations, and disrupted nocturnal sleep. Current treatments mainly provide partial symptomatic relief and do not correct the underlying orexin deficiency, highlighting the need for mechanism-based therapies. Oveporexton (TAK-861), an orally administered selective orexin receptor 2 (OX2R) agonist developed by Takeda Pharmaceuticals, represents the first approved therapy targeting the orexin pathway in NT1. By activating preserved OX2R signaling, oveporexton restores wakefulness regulation and alleviates multiple core symptoms of NT1. Its approval was aided by two global phase 3 trials which demonstrated significant improvements in wakefulness and cataplexy compared with placebo. Although its long-term safety, accessibility, and real-world efficacy need to be evaluated further, oveporexton represents a major advance toward disease mechanism-based treatment for NT1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.
Zitieren
APA
Sun, Y., & Gao, J. (2026). Oveporexton: The first-in-class orexin receptor 2 (OX2R) agonist approved for treatment of narcolepsy type 1 (NT1). Drug Discoveries & Therapeutics, 20(4), 357-359. https://doi.org/10.5582/ddt.2026.01056
Vancouver
Sun Y, Gao J. Oveporexton: The first-in-class orexin receptor 2 (OX2R) agonist approved for treatment of narcolepsy type 1 (NT1). Drug Discoveries & Therapeutics. 2026;20(4):357-359. doi:10.5582/ddt.2026.01056
BibTeX
@article{Sun2026,
author = {Sun, Yueyi and Gao, Jianjun},
title = {Oveporexton: The first-in-class orexin receptor 2 (OX2R) agonist approved for treatment of narcolepsy type 1 (NT1)},
journal = {Drug Discoveries & Therapeutics},
year = {2026},
volume = {20},
number = {4},
pages = {357--359},
doi = {10.5582/ddt.2026.01056}
}
EUVIMED